14 March 2023 - - The "United States Specialty Generics Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to Dublin-based ResearchAndMarkets.com's offering.

The United States specialty generics market size reached USD 23.6bn in 2021.

Looking forward, the publisher expects the market to reach USD 43.1bn by 2027, exhibiting a CAGR of 10.56% during 2021-2027.

Specialty generic drugs are the generic versions of specialty branded drugs once they lose patent protection.

These drugs are used to treat life threatening and serious health conditions such as cancer, autoimmune diseases, epilepsy, HIV, hepatitis, multiple sclerosis, rheumatoid arthritis, etc.

Specialty generics are economical compared to specialty drugs as they don't need to undergo the costly and time-consuming research and development procedures required for their branded versions.

Moreover, marketing and promotional expenses for speciality generics are also lower compared to their branded versions.

This results in significant savings for patients, government and healthcare providers. Moreover, the market is also being catalysed by a rising ageing population in the United States.

This has resulted in an increasing prevalence of various life-threatening diseases such as cancer, multiple sclerosis, hepatitis, HIV, autoimmune disease, etc.

For instance, the American cancer society estimated a total of 1,762,450 new cancer cases and 606,880 deaths from cancer in the United States for 2019.

Additionally, the patent expiration of several blockbuster branded specialty drugs is further expected to catalyse the market growth in the coming years.

The publisher provides an analysis of the key trends in each sub-segment of the United States specialty generics market report, along with forecasts for the period 2022-2027.

Our report has categorized the market based on route of administration, therapeutic application and distribution channel.